Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21

Benzinga · 3d ago
Morgan Stanley analyst Kallum Titchmarsh maintains Minimed Group (NASDAQ:MMED) with a Overweight and raises the price target from $19 to $21.